Directors at specialist pharmaceutical firm Vectura expect its 2020 financial results to be better than they expected following approval of its latest asthma treatment in the US. The firm will also benefit from millions of dollars in royalties and damages paid by pharma giant GlaxoSmithKline (GSK) following a US court case over infringement while...